458 related articles for article (PubMed ID: 30139745)
1. The non-enzymatic RAS effector RASSF7 inhibits oncogenic c-Myc function.
Kumaraswamy A; Mamidi A; Desai P; Sivagnanam A; Perumalsamy LR; Ramakrishnan C; Gromiha M; Rajalingam K; Mahalingam S
J Biol Chem; 2018 Oct; 293(40):15691-15705. PubMed ID: 30139745
[No Abstract] [Full Text] [Related]
2. MYC interaction with the tumor suppressive SWI/SNF complex member INI1 regulates transcription and cellular transformation.
Stojanova A; Tu WB; Ponzielli R; Kotlyar M; Chan PK; Boutros PC; Khosravi F; Jurisica I; Raught B; Penn LZ
Cell Cycle; 2016 Jul; 15(13):1693-705. PubMed ID: 27267444
[TBL] [Abstract][Full Text] [Related]
3. Miz-1 and Max compete to engage c-Myc: implication for the mechanism of inhibition of c-Myc transcriptional activity by Miz-1.
Bédard M; Maltais L; Montagne M; Lavigne P
Proteins; 2017 Feb; 85(2):199-206. PubMed ID: 27859590
[TBL] [Abstract][Full Text] [Related]
4. New structural determinants for c-Myc specific heterodimerization with Max and development of a novel homodimeric c-Myc b-HLH-LZ.
Beaulieu ME; McDuff FO; Frappier V; Montagne M; Naud JF; Lavigne P
J Mol Recognit; 2012 Jul; 25(7):414-26. PubMed ID: 22733550
[TBL] [Abstract][Full Text] [Related]
5. Myc phosphorylation in its basic helix-loop-helix region destabilizes transient α-helical structures, disrupting Max and DNA binding.
Macek P; Cliff MJ; Embrey KJ; Holdgate GA; Nissink JWM; Panova S; Waltho JP; Davies RA
J Biol Chem; 2018 Jun; 293(24):9301-9310. PubMed ID: 29695509
[TBL] [Abstract][Full Text] [Related]
6. The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells.
Lafita-Navarro MC; Liaño-Pons J; Quintanilla A; Varela I; Blanco R; Ourique F; Bretones G; Aresti J; Molina E; Carroll P; Hurlin P; Romero OA; Sanchez-Céspedes M; Eisenman RN; Delgado MD; León J
J Biol Chem; 2020 Feb; 295(7):2001-2017. PubMed ID: 31919096
[TBL] [Abstract][Full Text] [Related]
7. Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis.
Diolaiti D; McFerrin L; Carroll PA; Eisenman RN
Biochim Biophys Acta; 2015 May; 1849(5):484-500. PubMed ID: 24857747
[TBL] [Abstract][Full Text] [Related]
8. MYC the oncogene from hell: Novel opportunities for cancer therapy.
Papadimitropoulou A; Makri M; Zoidis G
Eur J Med Chem; 2024 Mar; 267():116194. PubMed ID: 38340508
[TBL] [Abstract][Full Text] [Related]
9. Sirt1 deacetylates c-Myc and promotes c-Myc/Max association.
Mao B; Zhao G; Lv X; Chen HZ; Xue Z; Yang B; Liu DP; Liang CC
Int J Biochem Cell Biol; 2011 Nov; 43(11):1573-81. PubMed ID: 21807113
[TBL] [Abstract][Full Text] [Related]
10. The Max b-HLH-LZ can transduce into cells and inhibit c-Myc transcriptional activities.
Montagne M; Beaudoin N; Fortin D; Lavoie CL; Klinck R; Lavigne P
PLoS One; 2012; 7(2):e32172. PubMed ID: 22384171
[TBL] [Abstract][Full Text] [Related]
11. Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Max heterodimeric leucine zipper.
Lavigne P; Crump MP; Gagné SM; Hodges RS; Kay CM; Sykes BD
J Mol Biol; 1998 Aug; 281(1):165-81. PubMed ID: 9680483
[TBL] [Abstract][Full Text] [Related]
12. HMG-I/Y, a new c-Myc target gene and potential oncogene.
Wood LJ; Mukherjee M; Dolde CE; Xu Y; Maher JF; Bunton TE; Williams JB; Resar LM
Mol Cell Biol; 2000 Aug; 20(15):5490-502. PubMed ID: 10891489
[TBL] [Abstract][Full Text] [Related]
13. BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.
Sharma N; Magistroni V; Piazza R; Citterio S; Mezzatesta C; Khandelwal P; Pirola A; Gambacorti-Passerini C
Mol Cancer; 2015 Jul; 14():132. PubMed ID: 26179066
[TBL] [Abstract][Full Text] [Related]
14. Biophysical characterization of the b-HLH-LZ of ΔMax, an alternatively spliced isoform of Max found in tumor cells: Towards the validation of a tumor suppressor role for the Max homodimers.
Maltais L; Montagne M; Bédard M; Tremblay C; Soucek L; Lavigne P
PLoS One; 2017; 12(3):e0174413. PubMed ID: 28350847
[TBL] [Abstract][Full Text] [Related]
15. Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression.
Si J; Yu X; Zhang Y; DeWille JW
Mol Cancer; 2010 Apr; 9():92. PubMed ID: 20426839
[TBL] [Abstract][Full Text] [Related]
16. Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene.
Demma MJ; Mapelli C; Sun A; Bodea S; Ruprecht B; Javaid S; Wiswell D; Muise E; Chen S; Zelina J; Orvieto F; Santoprete A; Altezza S; Tucci F; Escandon E; Hall B; Ray K; Walji A; O'Neil J
Mol Cell Biol; 2019 Nov; 39(22):. PubMed ID: 31501275
[TBL] [Abstract][Full Text] [Related]
17. MSSP promotes ras/myc cooperative cell transforming activity by binding to c-Myc.
Niki T; Izumi S; Saëgusa Y; Taira T; Takai T; Iguchi-Ariga SM; Ariga H
Genes Cells; 2000 Feb; 5(2):127-41. PubMed ID: 10672043
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic activity of the c-Myc protein requires dimerization with Max.
Amati B; Brooks MW; Levy N; Littlewood TD; Evan GI; Land H
Cell; 1993 Jan; 72(2):233-45. PubMed ID: 8425220
[TBL] [Abstract][Full Text] [Related]
19. Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.
Li S; He X; Gan Y; Zhang J; Gao F; Lin L; Qiu X; Yu T; Zhang X; Chen P; Tong J; Qian W; Xu Y
Theranostics; 2021; 11(7):3439-3451. PubMed ID: 33537096
[No Abstract] [Full Text] [Related]
20. Design and properties of a Myc derivative that efficiently homodimerizes.
Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
